Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Thödtmann, F; Theiss, F; Kemmerich, M; Heinrich, B; Laubenbacher, C; Quasthoff, S; Kau, R; Herzog, M; Diergarten, K; Hanauske, AR.
Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
Ann Oncol. 1998; 9(3):335-337
Doi: 10.1023/A:1008298915121
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Quasthoff Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Paclitaxel as single agent has shown marked activity in several malignancies. The aim of the present phase II trial was to determine the activity of paclitaxel/cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. PATIENTS AND METHODS: 200 mg/m2 paclitaxel was administered over three hours followed by cisplatin (100 mg/m2), repeated every 22 days. Twenty-eight patients were entered and received a total of 99 cycles (median 2, range 1-6). All patients were evaluable for toxicity, and 25 for response. RESULTS: Hematologic toxicities included leukopenia CTC grade 3 in 13 patients, and grade 4 in five patients, neutropenia grade 3 in nine patients, and grade 4 in eight patients, grade 3 anemia and grade 2 thrombocytopenia in one patient each. Non-hematologic toxicities included hypotension grade 2 (six patients), grade 3 (four patients), and grade 4 (two patients). A decline in renal function was observed in 15 courses and 10 patients, leading to a median delay of 2.5 days. Neurosensory and neuromotor toxicity grade 1 were observed in 13 patients (grade 2: 12 patients; grade 3: one patient), myalgia grade 3 in one patient, asthenia grade 3 in two and grade 4 in one patient. Partial responses were observed in 12 patients for an overall response rate of 48% (95% CI: 28%-68%) with a median response duration of 6.5 months (range 1-10 months). Stable disease was observed in seven patients, of who two also had clinical benefit. CONCLUSIONS: Paclitaxel 200 mg/m2 administered over three hours combined with cisplatin 100 mg/m2 is an active regimen warranting further evaluation.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Agents, Phytogenic - administration and dosage
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Carcinoma, Squamous Cell - drug therapy
- Cisplatin - administration and dosage
- Drug Administration Schedule - administration and dosage
- Female - administration and dosage
- Head and Neck Neoplasms - drug therapy
- Hematologic Diseases - chemically induced
- Humans - chemically induced
- Infusions, Intravenous - chemically induced
- Male - chemically induced
- Middle Aged - chemically induced
- Neoplasm Recurrence, Local - drug therapy
- Paclitaxel - administration and dosage
- Survival Rate - administration and dosage
- Treatment Outcome - administration and dosage
- Find related publications in this database (Keywords)
- head and neck cancer
- paclitaxel
- cisplatin
- phase II trial